We are live on ! Find out more
ARRY

Array Biopharma Inc
ARRY

Delisted

ARRY was delisted on the 29th of July, 2019.

Back to rankings

268 hedge funds and large institutions have $5.5B invested in Array Biopharma Inc in 2019 Q1 according to their latest regulatory filings, with 62 funds opening new positions, 101 increasing their positions, 75 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

338% more call options, than puts

Call options by funds: $89.5M | Put options by funds: $20.4M

114% more first-time investments, than exits

New positions opened: 62 | Existing positions closed: 29

83% more capital invested

Capital invested by funds: $3B → $5.5B (+$2.5B)

44% more funds holding in top 10

Funds holding in top 10: 9 → 13 (+4)

35% more repeat investments, than reductions

Existing positions increased: 101 | Existing positions reduced: 75

14% more funds holding

Funds holding: 236 → 268 (+32)

Holders
268
Holders Change
+32
Holders Change %
+13.56%
% of All Funds
5.8%
Holding in Top 10
13
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+44.44%
% of All Funds
0.28%
New
62
Increased
101
Reduced
75
Closed
29
Calls
$89.5M
Puts
$20.4M
Net Calls
+$69.1M
Net Calls Change
+$50.4M

Top Buyers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$123M
2
PA
Perceptive Advisors
New York
+$88M
3
MWNA
Marshall Wace North America
New York
+$52.9M
4
ACA
Avoro Capital Advisors
New York
+$41.6M
5
1832 Asset Management
1832 Asset Management
Ontario, Canada
+$33.4M

Top Sellers

1
RG
Redmile Group
California
-$114M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$84M
3
Millennium Management
Millennium Management
New York
-$30.8M
4
PAMU
Pictet Asset Management (UK)
United Kingdom
-$30.7M
5
BI
BVF Inc
California
-$27.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
Canada Life
176
Canada Life
Manitoba, Canada
$708K +$71.7K +3,443 +13%
OAM
177
Oppenheimer Asset Management
New York
$701K +$49.8K +2,394 +9%
TCS
178
Texas Children's
Texas
$621K -$936K -44,950 -64%
SCM
179
Silvant Capital Management
Georgia
$620K – – –
ARTA
180
A.R.T. Advisors
New York
$585K +$499K +23,986 New
ACM
181
AlphaCrest Capital Management
New York
$524K +$448K +21,500 New
B
182
Bailard
California
$517K -$146K -7,000 -25%
QIM
183
Quantitative Investment Management
Virginia
$516K +$441K +21,200 New
Wolverine Trading
184
Wolverine Trading
Illinois
$499K -$169K -8,126 -28%
FMT
185
First Mercantile Trust
Tennessee
$481K +$21K +1,010 +5%
SAM
186
Shell Asset Management
Netherlands
$463K – – –
TRSOTSOK
187
Teachers Retirement System of the State of Kentucky
Kentucky
$449K +$384K +18,432 New
SC
188
Slow Capital
California
$430K +$367K +17,623 New
AIP
189
Ameritas Investment Partners
Nebraska
$425K +$8.79K +422 +2%
TAM
190
Tocqueville Asset Management
New York
$420K +$359K +17,225 New
RJFSA
191
Raymond James Financial Services Advisors
Florida
$409K +$14.7K +706 +4%
ECM
192
Endurant Capital Management
California
$401K -$1.79M -85,898 -84%
SQA
193
Simon Quick Advisors
New Jersey
$387K -$1.52K -73 -0.5%
Man Group
194
Man Group
United Kingdom
$386K +$329K +15,813 New
HSBC Holdings
195
HSBC Holdings
United Kingdom
$371K +$317K +15,205 New
GC
196
Grimes & Company
Massachusetts
$341K – – –
Capital Fund Management (CFM)
197
Capital Fund Management (CFM)
France
$314K +$268K +12,885 New
SG Americas Securities
198
SG Americas Securities
New York
$309K +$264K +12,684 New
RJA
199
Raymond James & Associates
Florida
$305K +$46.2K +2,221 +22%
BCM
200
Bayesian Capital Management
New York
$290K +$248K +11,900 New
6 7
8
9 10

ARRY Hedge Fund Activity: Q1 2019 in Review

268 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q1 2019, worth a combined $5.5B — up 83% from $3B a quarter earlier.

Buyers outnumbered sellers: 62 funds opened new ARRY positions and 29 closed out — a net gain of 33 holders — while 101 added to existing stakes and 75 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $123M. The largest seller was Redmile Group, cutting an estimated $114M.

  • 268 institutional investors held Array Biopharma Inc (ARRY) as of Q1 2019, up from 236 in Q4 2018.
  • Funds reported $5.5B of Array Biopharma Inc stock for Q1 2019, up 83% quarter-over-quarter.
  • 62 funds opened new Array Biopharma Inc positions in Q1 2019 and 29 closed out, a net change of +33 holders.
  • The largest Array Biopharma Inc buyer in Q1 2019 was T. Rowe Price Associates, an estimated $123M added.
  • The largest Array Biopharma Inc seller in Q1 2019 was Redmile Group, an estimated $114M sold.

Based on aggregated 13F filings for Q1 2019.